IBS is a functional gastrointestinal disorder characterized by chronic abdominal pain or discomfort associated with altered bowel habits (constipation, diarrhea, or both) in the absence of identifiable structural, inflammatory, or biochemical pathology. The Rome IV criteria (2016) define IBS as recurrent abdominal pain on average at least one day per week in the last three months, associated with two or more of: (1) related to defecation, (2) associated with a change in stool frequency, or (3) associated with a change in stool form. Symptoms must have been present for 3 months with onset at least 6 months prior.
The current mechanistic model is biopsychosocial: IBS represents dysregulation of the gut-brain axis producing visceral hypersensitivity (amplified pain signaling from normal gut stimuli), altered intestinal motility, microbiome dysbiosis, increased intestinal permeability, and low-grade mucosal immune activation — all interacting with psychological factors (anxiety, depression, early life stress) and dietary triggers. No single mechanism explains all IBS presentations, which is why treatment responses vary widely and why a multimodal approach is most effective.
| Intervention | IBS Type | Evidence | Response Rate | Notes |
|---|---|---|---|---|
| Low-FODMAP diet | All subtypes | Strong (multiple RCTs) | 52–86% | 3-phase: elimination (6 weeks), reintroduction, personalization; dietitian essential; risk of nutritional deficit if elimination prolonged indefinitely |
| Gut-directed hypnotherapy | All subtypes | Strong (multiple RCTs) | 71% at 5 years | Most durable long-term response of any IBS intervention; Nerva app self-hypnosis shows 72% response in 6-week RCT; targets visceral hypersensitivity directly |
| Peppermint oil (enteric-coated) | IBS-D, mixed | Good (meta-analysis) | 40–57% | First-line pharmacotherapy; IBgard brand micropearls; 0.2–0.4mL before meals; avoid in GERD; very well tolerated |
| Soluble fiber (psyllium) | IBS-C, mixed | Good | Moderate | Psyllium (soluble) reduces IBS symptoms; insoluble fiber (wheat bran) may worsen them; start 5g/day with water |
| Rifaximin (Xifaxan) | IBS-D (non-constipated) | Good (N=1,260 RCTs) | 40% global relief | Non-absorbable antibiotic; targets SIBO as IBS driver; 550mg 3×/day × 14 days; effect lasts 3–6 months; retreatment effective; prescription required |
| Tricyclic antidepressants (low dose) | IBS-D, pain-predominant | Good (meta-analysis) | ~50% vs 30% placebo | Amitriptyline 10–25mg at night; reduces visceral hypersensitivity and slows transit; prescribed as gut-brain modulator, NOT for depression at these doses |
| Probiotics | All subtypes | Moderate (inconsistent) | Variable | Bifidobacterium infantis 35624 (Align): best single-strain IBS evidence; multispecies generally outperform single strains; AGA guideline: consider in clinical trial context |
| CBT (Cognitive Behavioral Therapy) | All subtypes | Good | 50–60% | Everitt 2019 (Gut, N=558): CBT significantly superior to usual care at 12 months; web-delivered CBT programs showing comparable efficacy to in-person; particularly effective with anxiety/depression comorbidity |
| Aerobic exercise | All subtypes | Good (underutilized) | ~50% improvement | Johannesson 2011 (American Journal of Gastroenterology, N=102, RCT): 12 weeks of 20–60 min moderate exercise 3–5×/week significantly reduced IBS severity vs sedentary controls; persistently underused as treatment despite strong evidence |
Step 1 — Confirm Rome IV diagnosis and exclude red flags: IBS is a clinical diagnosis — colonoscopy is NOT required in patients under 45 without red flags (rectal bleeding, unintentional weight loss, nocturnal symptoms, family history of colorectal cancer or IBD, iron deficiency anemia). Red flags warrant investigation. Test for celiac disease (anti-tTG IgA) in all IBS patients — celiac mimics IBS and affects 1–2% of the population; missed without specific testing.
Step 2 — Low-FODMAP diet trial (first-line dietary intervention): Work with a registered dietitian trained in FODMAP; elimination phase 4–6 weeks (remove high-FODMAP foods: excess fructose, lactose, fructans/GOS, polyols); if symptomatic improvement, proceed to systematic reintroduction to identify personal triggers; the goal is the most liberal diet that controls symptoms, not permanent elimination of all FODMAPs (which depletes beneficial Bifidobacterium).
Step 3 — Add peppermint oil for acute symptom control: Enteric-coated peppermint oil 0.2–0.4mL (1–2 capsules) 30–90 minutes before meals; use for 4–8 weeks; compatible with dietary intervention; particularly effective for cramping, spasm, and urgency in IBS-D.
Step 4 — Address the gut-brain axis directly: Gut-directed hypnotherapy (Nerva app: evidence-based audio program); CBT if anxiety or depression is comorbid; aerobic exercise 3–5×/week (dramatically underutilized — exercise reduces IBS severity as much as many medications); stress management (the gut-brain axis means psychological stress directly amplifies visceral pain signals).
Subtype-specific additions: IBS-C: psyllium fiber 10–15g/day in divided doses with plenty of water; linaclotide or lubiprostone (prescription) for refractory IBS-C. IBS-D: loperamide for urgency management; consider rifaximin 14-day course if SIBO suspected; tricyclic antidepressants 10–25mg at night for pain-predominant with physician oversight.
As an Amazon Associate, GutCode earns from qualifying purchases made through links on this page. This does not affect the price you pay.